Catalogo dei prodotti della ricerca

RIGGIO, Oliviero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.483
EU - Europa 3.719
AS - Asia 2.063
AF - Africa 300
SA - Sud America 65
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 19.637
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.239
IT - Italia 1.557
SG - Singapore 837
IN - India 628
CN - Cina 501
DE - Germania 444
UA - Ucraina 401
SE - Svezia 354
FI - Finlandia 337
BJ - Benin 204
GB - Regno Unito 135
CA - Canada 130
BG - Bulgaria 122
BZ - Belize 93
FR - Francia 88
RU - Federazione Russa 73
TG - Togo 73
IE - Irlanda 70
AR - Argentina 53
ID - Indonesia 50
BE - Belgio 27
NL - Olanda 24
MX - Messico 21
RO - Romania 17
ZA - Sudafrica 15
CH - Svizzera 14
ES - Italia 10
TR - Turchia 10
PK - Pakistan 8
AT - Austria 6
HR - Croazia 6
CL - Cile 5
CZ - Repubblica Ceca 5
TW - Taiwan 5
AL - Albania 4
EU - Europa 4
PL - Polonia 4
SC - Seychelles 4
KR - Corea 3
PT - Portogallo 3
RS - Serbia 3
AU - Australia 2
BR - Brasile 2
DK - Danimarca 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
HK - Hong Kong 2
JP - Giappone 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
LV - Lettonia 2
NO - Norvegia 2
PH - Filippine 2
SI - Slovenia 2
TH - Thailandia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BY - Bielorussia 1
CO - Colombia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
MT - Malta 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 19.637
Salva come PNG Salva come JPEG
Città #
Fairfield 2.083
Woodbridge 951
Ashburn 931
Chandler 796
Houston 716
Seattle 703
Cambridge 673
Wilmington 657
Singapore 570
Ann Arbor 488
Dearborn 434
Princeton 430
Fremont 392
San Paolo di Civitate 364
Rome 329
Plano 293
San Jose 231
Lawrence 218
Beijing 209
Frankfurt am Main 208
Fasano 201
Millbury 192
Santa Clara 191
Jacksonville 160
San Diego 153
Boston 150
Sofia 121
Dallas 101
Belize City 93
New York 93
Andover 87
Bremen 80
Ottawa 77
Lomé 73
Dublin 63
Helsinki 57
Milan 53
Federal 52
Saint Louis 52
Des Moines 49
Norwalk 48
Jakarta 47
San Mateo 46
Toronto 46
Boardman 44
Falls Church 42
Atlanta 40
Moscow 38
Southend 36
Hefei 34
Los Angeles 34
Nanjing 31
Chicago 29
Columbus 27
Bühl 26
Jinan 25
Brussels 24
Falkenstein 24
Kunming 23
Naples 23
Washington 22
Guangzhou 21
London 19
Mannheim 18
Nanchang 18
Mexico City 15
Auburn Hills 14
Bologna 14
Florence 13
Phoenix 12
Indiana 10
Johannesburg 10
Padova 10
Shanghai 10
Fuzhou 9
Baotou 8
Concorezzo 8
Istanbul 8
San Nicola la Strada 8
Buffalo 7
Pomezia 7
Shenyang 7
Bern 6
Cesena 6
Genzano Di Roma 6
Hebei 6
Orem 6
Redwood City 6
Teramo 6
Turin 6
Verona 6
Amsterdam 5
Changsha 5
Grossalmerode 5
Hsinchu 5
Hyderabad 5
Islamabad 5
Lappeenranta 5
Livorno 5
Montréal 5
Totale 14.828
Salva come PNG Salva come JPEG
Nome #
Poliprotect vs omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions. A randomized, controlled trial 205
Semeiotica Medica e Metodologia Clinica, 3ª ed 176
Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis 141
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 139
Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension 126
Low-grade endotoxemia and platelet activation in cirrhosis 123
Management of Hepatic Encephalopathy as an Inpatient 122
Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: Time to update the guidelines? 115
Evidence of Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy 111
A low muscle mass increases mortality in compensated cirrhotic patients with sepsis 111
Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial 109
High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: A case-control study 109
Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis 106
The animal naming test: an easy tool for the assessment of hepatic encephalopathy 105
No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt 103
Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors 103
Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? 100
Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients 98
BACTERIAL INFECTIONS AND SEPSIS ACUTELY DETERIORATE LIVER FUNCTION IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY 98
Beta-blokers in patients with cirrhosis and infection: don't blame too soon. 97
Cirrhotic patients are at risk for health care-associated bacterial infections. 97
Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt 97
Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt 96
Hemostatic balance in patients with liver cirrhosis. report of a consensus conference 96
The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease 96
A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy 95
Can an incomplete stent expansion modulate the effects of TIPS? 94
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis 94
Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis 94
CARBON TETRACHLORIDE-INDUCED EXPERIMENTAL CIRRHOSIS IN THE RAT - A REAPPRAISAL OF THE MODEL 93
Does nutritional status influence the outcome in patients undergoing liver transplantation in the “MELD” era? 93
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 93
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. 91
Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis 91
Ongoing prothrombotic state in the portal circulation of cirrhotic patients 90
May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease? 90
Portal Hypertension Related to Schistosomiasis Treated with a Transjugular Intrahepatic Portosystemic Shunt 89
Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice 88
Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease 87
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. 87
A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients 85
Zinc, ammonia, and Helicobacter pylori infection in liver cirrhosis. 85
Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story? 84
Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients 84
Dietary and nutritional indications in hepatic encephalopathy 84
Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis 84
OXIDATIVE STRESS AND INFLAMMATION IN LIVER CIRRHOSIS: ROLE OF N-6/N-3 POLYUNSATURATED FATTY ACIDS BALANCE 83
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey 83
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (tips): PTFE-covered stent grafts versus bare stents 83
Clotting activation after transjugular intrahepatic portosystemic stent shunt 82
VIDEOCAPSULE ENDOSCOPY IN PATIENTS WITH PORTAL HYPERTENSION: SMALL BOWEL FINDINGS BEFORE AND FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT 82
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt 81
Modification of cardiac function in cirrhotic patients with and without ascites 81
Progression of low risk esophageal varices in cirrhotic patients 81
Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice 81
MELD, PROTEIN MALNUTRITION AND PREVIOUS INFECTIONS ARE PREDICTORS OF BACTERIAL INFECTIONS AND SEPSIS IN CIRRHOTIC PATIENTS 81
A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis 81
Idiopathic noncirrhotic portal hypertension: current perspectives 80
An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics. A randomized trial 80
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 80
Natural history of low risk esophageal varices in cirrhotic patients 79
Endoscopic screening for esophageal varices in cirrhotic patients 79
Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation 79
Do We Really Need Alternatives to Polymorphonuclear Cells Counting in Ascitic Fluid? 79
IN VITRO EFFECT OF n-6/n-3 POLYUNSATURATED FATTY ACIDS ON PLATELET NOX2-MEDIATED OXIDATIVE STRESS IN LIVER CIRRHOSIS 79
A comparison of skinfold anthropometry and dual-energy X ray absorptiometry for the evaluation of body fat in cirrhotic patients. 79
Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass 79
Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: Results of a prospective study 79
Small hepatic veins Budd-Chiari syndrome 79
Prediction of hepatic encephalopathy: Why disregard well-known risk factors? 79
Hepatic Encephalopathy Expands the Predictivity of Meld in Liver Transplant Setting: Evidence by Means of two Independent Cohorts 79
Is hyperammonemia really the true cause of altered neuropsychology, brain MR spectroscopy and magnetization transfer after an oral amino acid load in cirrhosis? 79
Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis 78
Role of the determination of partial pressure of ammonia in cirrhotic patients with hepatic encephalopathy 78
Nutritional status: its influence on the outcome of patients undergoing liver transplantation 78
The modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt 78
Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? 78
PERSISTENCE OF COGNITIVE IMPAIRMENT AFTER OVERT HEPATIC ENCEPHALOPATHY: AN INTERNATIONAL, MULTI-CENTER PROSPECTIVE STUDY 77
Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation 77
PTFE-covered stent-grafts for tips procedure: One-year patency and clinical results 77
Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis 77
Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results 77
Ticlopidine-induced cholestasis 77
Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. 77
A comparison of cell blood analyzer and manual hemacytometer for polymorphonuclear cell count in the ascttic fluid in cirrhotic patients with and without spontaneous bacterial peritonitis 76
Aminoacid imbalance and malnutrition in liver cirrhosis. 76
Quality of life in patients with minimal hepatic encephalopathy 76
Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS 76
Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt 76
ESPEN guidelines on enteral nutrition: Liver disease 75
Hepatic encephalopathy: You should only comment on what you have actually measured 75
Malnutrition is a risk factor in cirrhotic patients undergoing surgery 75
Early postprandial energy expenditure and macronutrient use after a mixed meal in cirrhotic patients. 75
Increased risk of cognitive impairment in cirrhotic patients with bacterial infections 75
Nutritional Status and Liver Transplantation 75
Hepatic encephalopathy therapy: An overview. 74
Management of refractory hepatic encephalopathy after insertion of TIPS: Long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft 74
MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. 74
The treatment of hepatic encephalopathy 73
Erectile dysfunction in patients with liver cirrhosis 73
Totale 8.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.990 0 0 0 0 0 1.767 682 512 499 267 157 106
2020/20211.788 160 187 141 174 29 79 56 165 152 309 105 231
2021/20223.432 28 197 314 73 461 83 92 353 434 248 451 698
2022/20233.694 716 794 423 561 282 283 35 143 274 41 83 59
2023/20241.773 99 213 101 106 193 319 80 97 11 227 161 166
2024/20251.279 129 239 276 146 284 205 0 0 0 0 0 0
Totale 20.407